MYbank Launches AI-Enabled System for SME Money Management at Shanghai’s INCLUSION Conference
6.9.2024 08:16:00 CEST | Business Wire | Press release
MYbank, a leading digital bank in China and an associate of Ant Group, today introduced its AI-enabled system (Cuckoo System) for small and micro-sized enterprise (SME) money management at the 2024 INCLUSION·Conference on the Bund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905984463/en/
MYbank President Feng Liang introduces the AI-enabled system (Cuckoo System) for SME money management at the 2024 INCLUSION·Conference on the Bund. (Photo: Business Wire)
The system forecasts the cash flow of SMEs across various industries, assisting bank-affiliated investment management companies in more effectively anticipating the timing of SMEs' subscriptions and redemptions of investment products and helping SMEs generate reasonable returns from their idle cash. By aligning financial offerings with the operational cycles of SMEs, the system helps maximize efficiency in their financial management.
Feng Liang, MYbank President, highlighted the liquidity management challenges faced by SMEs: While SMEs may not prioritize high returns, they require investment products that offer a high level of capital security, align with their variable cash flow cycles, and provide stable returns.
“As of the end of 2023, MYbank has served over 53 million SMEs cumulatively. MYbank aims to leverage its deep understanding of SMEs' needs and cash flow, along with AI technology and the convenience of digital banking, to create an advanced money management experience for SMEs and support the growth of the real economy,” said Liang.
Powered by Ant Group's BaiLing foundation model, the system utilizes a time-series encoder to create highly accurate cash flow prediction models for SMEs across various sectors, including e-commerce, retail, and agriculture, achieving an accuracy rate of over 95%. Building on these cash flow predictions, the system also models the likelihood of future investment product purchases and redemptions. These timely insights enable bank-affiliated investment management companies to optimize fund utilization and improve asset allocation efficiency by 10%, thereby enhancing overall product returns.
As of September 2024, MYbank has established partnerships with 23 bank-affiliated investment management companies, five of which have closely adopted the system to optimize seven SME-focused investment management products.
According to McKinsey, the bank-affiliated investment management market is projected to reach 50 trillion yuan by 2030, with the user base expected to grow to 200 million. SMEs are highlighted as one of the most promising customer segments, with their market contribution potentially doubling over the next five years, as noted in McKinsey’s report, “Bank-affiliated Investment Management Market Trends and Opportunities for SMEs,” unveiled at the INCLUSION Conference.
About MYbank
Founded in 2015 with a focus on serving SMEs and farmers, MYbank was among the first group of pilot private commercial banks in China. It was also the first bank in China to deploy its core banking system entirely on the cloud without any physical branches.
MYbank pioneered the “310 model” for SME financing, which offers a collateral-free business loan that takes less than three minutes to apply on a mobile phone, less than one second to approve and requires zero human interaction.
In addition to advanced risk-management solutions, MYbank has harnessed technologies such as AI and remote sensing to streamline credit services for farmers. This approach eliminates the need for lengthy processes or paper documentation, making digital loans more accessible to them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905984463/en/
Contacts
Media Inquiries
Media Inquiries
MYbank: mediapress@service.mybank.cn
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom